[go: up one dir, main page]

GB201614897D0 - Compositions and uses thereof - Google Patents

Compositions and uses thereof

Info

Publication number
GB201614897D0
GB201614897D0 GBGB1614897.5A GB201614897A GB201614897D0 GB 201614897 D0 GB201614897 D0 GB 201614897D0 GB 201614897 A GB201614897 A GB 201614897A GB 201614897 D0 GB201614897 D0 GB 201614897D0
Authority
GB
United Kingdom
Prior art keywords
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1614897.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Manchester Metropolitan University
Original Assignee
Manchester Metropolitan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manchester Metropolitan University filed Critical Manchester Metropolitan University
Priority to GBGB1614897.5A priority Critical patent/GB201614897D0/en
Publication of GB201614897D0 publication Critical patent/GB201614897D0/en
Priority to PCT/GB2017/052541 priority patent/WO2018042182A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB1614897.5A 2016-09-02 2016-09-02 Compositions and uses thereof Ceased GB201614897D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1614897.5A GB201614897D0 (en) 2016-09-02 2016-09-02 Compositions and uses thereof
PCT/GB2017/052541 WO2018042182A1 (en) 2016-09-02 2017-09-01 Compositions and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614897.5A GB201614897D0 (en) 2016-09-02 2016-09-02 Compositions and uses thereof

Publications (1)

Publication Number Publication Date
GB201614897D0 true GB201614897D0 (en) 2016-10-19

Family

ID=57140016

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1614897.5A Ceased GB201614897D0 (en) 2016-09-02 2016-09-02 Compositions and uses thereof

Country Status (2)

Country Link
GB (1) GB201614897D0 (en)
WO (1) WO2018042182A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292612A4 (en) * 2021-02-15 2025-02-19 Canon Medical Systems Corporation Human denatured crp specific neutralizing antibody, and medicine and anti-inflammatory agent containing said antibody
CN113278078B (en) * 2021-05-25 2023-03-21 西南医科大学 Polypeptide sequence and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102703388B (en) * 2012-04-23 2014-01-15 王俊宏 Anti-human mCRP protein monoclonal antibodies, hybridoma cell lines and kits

Also Published As

Publication number Publication date
WO2018042182A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
SI3580561T1 (en) Hla-based methods and compositions and uses thereof
IL271275A (en) Compositions comprising curons and uses thereof
IL250568B (en) Anti-methanogenic compositions and uses thereof
IL264446A (en) Compounds and compositions and uses thereof
ZA201803451B (en) Probiotic compositions and uses thereof
GB2564510B (en) Compositions and methods and uses relating thereto
GB201706352D0 (en) Methods compositions and uses relating thereto
GB201706355D0 (en) Methods compositions and uses relating thereto
GB201706356D0 (en) Methods compositions and uses relating thereto
GB201502002D0 (en) Uses and compositions
GB201608762D0 (en) Compositions and uses thereof
GB201715785D0 (en) Methods compositions and uses relating thereto
SG10202100751YA (en) Compounds and compositions and uses thereof
GB201621294D0 (en) Compositions and uses and methods relating thereto
GB202004930D0 (en) Composition and uses thereof
GB201715820D0 (en) Compositions and methods
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
GB201502026D0 (en) Uses and compositions
GB201501991D0 (en) Uses and compositions
GB201716599D0 (en) Compositions and methods and uses relating thereto
GB201614897D0 (en) Compositions and uses thereof
GB201712592D0 (en) Novel compositions and uses thereof
GB201511886D0 (en) Uses and compositions
GB201812952D0 (en) Compositions and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)